Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

Summary

The most promising chimeric natriuretic peptide designed and studied by our group has been CD-NP which has anti-fibrotic and cardioprotective properties in vivo, vitro and in normal volunteers and human heart failure patients. Since left ventricular assist device (LVAD) can not reverse remodeling of the heart whereas it can improve hemodynamics, CD-NP may be novel anti-fibrotic and anti-remodeling drug as co-therapy during LVAD support.

Timeline

Start

2013-04

Primary completion

2016-05

Completion

2016-08

Drugs

Indications